Literature DB >> 19018450

The genomic profile of the cerebral cortex after closed head injury in mice: effects of minocycline.

Peter J Crack1, Jodee Gould, Nicole Bye, Shelley Ross, Uğur Ali, Mark D Habgood, Cristina Morganti-Kossman, Norman R Saunders, Paul J Hertzog.   

Abstract

Microarray analysis was used to delineate gene expression patterns and profile changes following traumatic brain injury (TBI) in mice. A parallel microarray analysis was carried out in mice with TBI that were subsequently treated with minocycline, a drug proposed as a neuroprotectant in other neurological disorders. The aim of this comparison was to identify pathways that may be involved in secondary injury processes following TBI and potential specific pathways that could be targeted with second generation therapeutics for the treatment of neurotrauma patients. Gene expression profiles were measured with the compugen long oligo chip and real-time PCR was used to validate microarray findings. A pilot study of effect of minocycline on gene expression following TBI was also carried out. Gene ontology comparison analysis of sham TBI and minocycline treated brains revealed biological pathways with more genes differentially expressed than predicted by chance. Among 495 gene ontology categories, the significantly different gene ontology groups included chemokines, genes involved in cell surface receptor-linked signal transduction and pro-inflammatory cytokines. Expression levels of some key genes were validated by real-time quantitative PCR. This study confirms that multiple regulatory pathways are affected following brain injury and demonstrates for the first time that specific genes and molecular networks are affected by minocycline following brain injury.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19018450     DOI: 10.1007/s00702-008-0145-1

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  45 in total

1.  Transient neuroprotection by minocycline following traumatic brain injury is associated with attenuated microglial activation but no changes in cell apoptosis or neutrophil infiltration.

Authors:  Nicole Bye; Mark D Habgood; Jennifer K Callaway; Nakisa Malakooti; Ann Potter; Thomas Kossmann; M Cristina Morganti-Kossmann
Journal:  Exp Neurol       Date:  2006-12-22       Impact factor: 5.330

2.  Regulation of chemokines and chemokine receptors after experimental closed head injury.

Authors:  V I Otto; P F Stahel; M Rancan; K Kariya; E Shohami; I Yatsiv; H P Eugster; T Kossmann; O Trentz; M C Morganti-Kossmann
Journal:  Neuroreport       Date:  2001-07-03       Impact factor: 1.837

3.  Intracellular protein therapy with SOCS3 inhibits inflammation and apoptosis.

Authors:  Daewoong Jo; Danya Liu; Shan Yao; Robert D Collins; Jacek Hawiger
Journal:  Nat Med       Date:  2005-07-10       Impact factor: 53.440

4.  Interleukin-6 and its soluble receptor in serum and cerebrospinal fluid after cerebral trauma.

Authors:  V H Hans; T Kossmann; H Joller; V Otto; M C Morganti-Kossmann
Journal:  Neuroreport       Date:  1999-02-05       Impact factor: 1.837

5.  Chlortetracycline and demeclocycline inhibit calpains and protect mouse neurons against glutamate toxicity and cerebral ischemia.

Authors:  Susan X Jiang; Jittiwud Lertvorachon; Sheng T Hou; Yasuo Konishi; Jacqueline Webster; Geoff Mealing; Eric Brunette; Joseph Tauskela; Edward Preston
Journal:  J Biol Chem       Date:  2005-08-09       Impact factor: 5.157

6.  IL-10 levels in cerebrospinal fluid and serum of patients with severe traumatic brain injury: relationship to IL-6, TNF-alpha, TGF-beta1 and blood-brain barrier function.

Authors:  E Csuka; M C Morganti-Kossmann; P M Lenzlinger; H Joller; O Trentz; T Kossmann
Journal:  J Neuroimmunol       Date:  1999-11-15       Impact factor: 3.478

Review 7.  Cytokines and chemokines as mediators of protection and injury in the central nervous system assessed in transgenic mice.

Authors:  J Wang; V C Asensio; I L Campbell
Journal:  Curr Top Microbiol Immunol       Date:  2002       Impact factor: 4.291

Review 8.  Activation of c-fos in the brain.

Authors:  D G Herrera; H A Robertson
Journal:  Prog Neurobiol       Date:  1996-10       Impact factor: 11.685

9.  Biphasic expression of activating transcription factor-3 in neurons after cerebral infarction.

Authors:  Norihiro Ohba; Mitsuyo Maeda; Saya Nakagomi; Michinari Muraoka; Hiroshi Kiyama
Journal:  Brain Res Mol Brain Res       Date:  2003-07-23

10.  Differential regulation of the monocytic calcium-binding peptides macrophage-inhibiting factor related protein-8 (MRP8/S100A8) and allograft inflammatory factor-1 (AIF-1) following human traumatic brain injury.

Authors:  R Beschorner; S Engel; M Mittelbronn; D Adjodah; K Dietz; H J Schluesener; R Meyermann
Journal:  Acta Neuropathol       Date:  2000-12       Impact factor: 17.088

View more
  20 in total

Review 1.  A review of neuroprotection pharmacology and therapies in patients with acute traumatic brain injury.

Authors:  Kevin W McConeghy; Jimmi Hatton; Lindsey Hughes; Aaron M Cook
Journal:  CNS Drugs       Date:  2012-07-01       Impact factor: 5.749

Review 2.  Bridge between neuroimmunity and traumatic brain injury.

Authors:  Matthew L Kelso; Howard E Gendelman
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

3.  Osteopontin expression in acute immune response mediates hippocampal synaptogenesis and adaptive outcome following cortical brain injury.

Authors:  Julie L Chan; Thomas M Reeves; Linda L Phillips
Journal:  Exp Neurol       Date:  2014-08-21       Impact factor: 5.330

4.  Comparison of the effect of minocycline and simvastatin on functional recovery and gene expression in a rat traumatic brain injury model.

Authors:  Cole Vonder Haar; Gail D Anderson; Brandy E Elmore; Lynn H Moore; Amanda M Wright; Eric D Kantor; Fred M Farin; Theo K Bammler; James W MacDonald; Michael R Hoane
Journal:  J Neurotrauma       Date:  2014-01-20       Impact factor: 5.269

5.  Strong Correlation of Genome-Wide Expression after Traumatic Brain Injury In Vitro and In Vivo Implicates a Role for SORLA.

Authors:  Michael R Lamprecht; Benjamin S Elkin; Kartik Kesavabhotla; John F Crary; Jennifer L Hammers; Jimmy W Huh; Ramesh Raghupathi; Barclay Morrison
Journal:  J Neurotrauma       Date:  2016-04-19       Impact factor: 5.269

Review 6.  Involvement of pro- and anti-inflammatory cytokines and chemokines in the pathophysiology of traumatic brain injury.

Authors:  Jenna M Ziebell; Maria Cristina Morganti-Kossmann
Journal:  Neurotherapeutics       Date:  2010-01       Impact factor: 7.620

Review 7.  Inflammatory reaction after traumatic brain injury: therapeutic potential of targeting cell-cell communication by chemokines.

Authors:  Stefka Gyoneva; Richard M Ransohoff
Journal:  Trends Pharmacol Sci       Date:  2015-05-13       Impact factor: 14.819

8.  Mild traumatic brain injury is associated with reduced cortical thickness in those at risk for Alzheimer's disease.

Authors:  Jasmeet P Hayes; Mark W Logue; Naomi Sadeh; Jeffrey M Spielberg; Mieke Verfaellie; Scott M Hayes; Andrew Reagan; David H Salat; Erika J Wolf; Regina E McGlinchey; William P Milberg; Annjanette Stone; Steven A Schichman; Mark W Miller
Journal:  Brain       Date:  2017-03-01       Impact factor: 13.501

9.  Modulation of LPA receptor expression in the human brain following neurotrauma.

Authors:  Tony Frugier; Duncan Crombie; Alison Conquest; Frisca Tjhong; Caroline Taylor; Tejal Kulkarni; Catriona McLean; Alice Pébay
Journal:  Cell Mol Neurobiol       Date:  2011-01-15       Impact factor: 5.046

10.  Acute or Delayed Treatment with Anatabine Improves Spatial Memory and Reduces Pathological Sequelae at Late Time-Points after Repetitive Mild Traumatic Brain Injury.

Authors:  Scott Ferguson; Benoit Mouzon; Daniel Paris; Destinee Aponte; Laila Abdullah; William Stewart; Michael Mullan; Fiona Crawford
Journal:  J Neurotrauma       Date:  2017-01-20       Impact factor: 5.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.